{"id":"https://openalex.org/W2019500932","doi":"https://doi.org/10.1179/joc.2007.19.3.322","title":"Docetaxel-Ifosfamide Combination in Patients with Advanced Breast Cancer Failing Prior Anthracycline- Based Regimens: Results of a Phase I-II Study","display_name":"Docetaxel-Ifosfamide Combination in Patients with Advanced Breast Cancer Failing Prior Anthracycline- Based Regimens: Results of a Phase I-II Study","publication_year":2007,"publication_date":"2007-06-01","ids":{"openalex":"https://openalex.org/W2019500932","doi":"https://doi.org/10.1179/joc.2007.19.3.322","mag":"2019500932","pmid":"https://pubmed.ncbi.nlm.nih.gov/17594929"},"language":"en","primary_location":{"id":"doi:10.1179/joc.2007.19.3.322","doi":"https://doi.org/10.1179/joc.2007.19.3.322","is_oa":false,"landing_page_url":"https://doi.org/10.1179/joc.2007.19.3.322","pdf_url":null,"source":{"id":"https://openalex.org/S127202688","display_name":"Journal of Chemotherapy","issn_l":"1120-009X","issn":["1120-009X","1973-9478"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Chemotherapy","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5072956257","display_name":"Christos Kosmas","orcid":"https://orcid.org/0000-0001-6790-5785","observed_orcids":["https://orcid.org/0000-0001-6790-5785"]},"institutions":[{"id":"https://openalex.org/I4210132093","display_name":"Metaxa Hospital","ror":"https://ror.org/03v7hnv07","country_code":"GR","type":"healthcare","lineage":["https://openalex.org/I4210132093"]}],"countries":["GR"],"is_corresponding":false,"raw_author_name":"C. Kosmas","raw_affiliation_strings":["Department of Medicine, 2nd Division of Medical Oncology, Metaxa Cancer Hospital, Piraeus, Greece"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, 2nd Division of Medical Oncology, Metaxa Cancer Hospital, Piraeus, Greece","institution_ids":["https://openalex.org/I4210132093"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110386215","display_name":"N. B. Tsavaris","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"N. Tsavaris","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029045590","display_name":"Nicolas Mylonakis","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"N. Mylonakis","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066518344","display_name":"Georgios Tsakonas","orcid":"https://orcid.org/0000-0003-4397-7391","observed_orcids":["https://orcid.org/0000-0003-4397-7391"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. Tsakonas","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004016557","display_name":"Argyris Gassiamis","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Gassiamis","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108195775","display_name":"Helias Skopelitis","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H. Skopelitis","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001577925","display_name":"Aristidis Polyzos","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Polyzos","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113734751","display_name":"Nicholaos A. Malamos","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"N. Malamos","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5028501800","display_name":"Athanasios Karabelis","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Karabelis","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.3575,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":{"value":0.65969446,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"19","issue":"3","first_page":"322","last_page":"331"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.9096999764442444,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.9096999764442444,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.08569999784231186,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/docetaxel","display_name":"docetaxel","score":0.9890000224113464},{"id":"https://openalex.org/keywords/ifosfamide","display_name":"ifosfamide","score":1.0},{"id":"https://openalex.org/keywords/advanced-breast-cancer","display_name":"advanced breast cancer","score":0.7749999761581421},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.9139999747276306},{"id":"https://openalex.org/keywords/anthracycline-refractory-disease","display_name":"anthracycline-refractory disease","score":0.9039999842643738},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.8479999899864197},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8650000095367432},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.9890000224113464},{"id":"https://openalex.org/keywords/febrile-neutropenia","display_name":"febrile neutropenia","score":0.972000002861023},{"id":"https://openalex.org/keywords/g-csf-prophylaxis","display_name":"G-CSF prophylaxis","score":0.8989999890327454},{"id":"https://openalex.org/keywords/response-rate","display_name":"response rate","score":0.574999988079071},{"id":"https://openalex.org/keywords/survival","display_name":"survival","score":0.4440000057220459},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.3319999873638153},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.39399999380111694},{"id":"https://openalex.org/keywords/taxanes","display_name":"taxanes","score":0.3400000035762787},{"id":"https://openalex.org/keywords/alkylating-agents","display_name":"alkylating agents","score":0.968999981880188},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.3799999952316284}],"concepts":[{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.8968207240104675},{"id":"https://openalex.org/C2777506904","wikidata":"https://www.wikidata.org/wiki/Q418560","display_name":"Ifosfamide","level":4,"score":0.8328741788864136},{"id":"https://openalex.org/C2776802502","wikidata":"https://www.wikidata.org/wiki/Q417589","display_name":"Anthracycline","level":4,"score":0.7918856739997864},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6968660354614258},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5976808071136475},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5125734210014343},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4768587052822113},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.44908541440963745},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.44702035188674927},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4234747886657715},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.41219067573547363},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.11498275399208069}],"mesh":[{"descriptor_ui":"D000077143","descriptor_name":"Docetaxel","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007069","descriptor_name":"Ifosfamide","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009362","descriptor_name":"Neoplasm Metastasis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011994","descriptor_name":"Recombinant Proteins","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016179","descriptor_name":"Granulocyte Colony-Stimulating Factor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D043823","descriptor_name":"Taxoids","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1179/joc.2007.19.3.322","doi":"https://doi.org/10.1179/joc.2007.19.3.322","is_oa":false,"landing_page_url":"https://doi.org/10.1179/joc.2007.19.3.322","pdf_url":null,"source":{"id":"https://openalex.org/S127202688","display_name":"Journal of Chemotherapy","issn_l":"1120-009X","issn":["1120-009X","1973-9478"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Chemotherapy","raw_type":"journal-article"},{"id":"pmid:17594929","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17594929","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of chemotherapy (Florence, Italy)","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":22,"referenced_works":["https://openalex.org/W43422572","https://openalex.org/W99352839","https://openalex.org/W1554317310","https://openalex.org/W1890813079","https://openalex.org/W1938913229","https://openalex.org/W1940754997","https://openalex.org/W1955744924","https://openalex.org/W1965352960","https://openalex.org/W1983009918","https://openalex.org/W2002367676","https://openalex.org/W2029409133","https://openalex.org/W2044463482","https://openalex.org/W2086909567","https://openalex.org/W2093749063","https://openalex.org/W2139996054","https://openalex.org/W2141056749","https://openalex.org/W2157883360","https://openalex.org/W2167805334","https://openalex.org/W2199860498","https://openalex.org/W2259919828","https://openalex.org/W2399496714","https://openalex.org/W3041047318"],"related_works":["https://openalex.org/W1993316442","https://openalex.org/W2417406581","https://openalex.org/W2042513738","https://openalex.org/W2019967763","https://openalex.org/W2412203479","https://openalex.org/W2086909567","https://openalex.org/W1976701769","https://openalex.org/W2125025657","https://openalex.org/W2087125925","https://openalex.org/W2106964779"],"abstract_inverted_index":{"The":[0,246,363],"established":[1],"clinical":[2,35],"activity":[3,36,379],"of":[4,37,66,71,132,141,177,206,275,288,340,355,380,389,403],"docetaxel":[5,72,400],"and":[6,34,110,123,137,165,168,198,243,261,285,333,375],"ifosfamide":[7,83],"as":[8,150,185,352],"single":[9],"agents":[10,409],"in":[11,41,64,116,153,229,273,286,307,314,322,327,331,338,344,384],"anthracycline":[12],"pre-treated":[13],"breast":[14,49],"cancer,":[15,50],"led":[16],"us":[17],"to":[18,24,112],"conduct":[19],"a":[20,107,129,353],"phase":[21,154,189,230,349,365,386,395],"I-II":[22,366],"study":[23,346,367],"define":[25],"the":[26,38,169,186,204,345,360,370,373,377,381,385,390,404],"maximum":[27],"tolerated":[28],"dose":[29,61],"(MTD),":[30],"dose-limiting":[31,102],"toxicities":[32,270,300],"(DLTs),":[33],"docetaxel+ifosfamide":[39],"combination":[40,383],"this":[42],"setting.":[43],"Patients":[44],"with":[45,68,128,214,277,406],"histologically":[46],"confirmed":[47],"metastatic":[48],"after":[51,208,359],"failure":[52,358],"on":[53,78,225],"prior":[54],"anthracycline-based":[55],"chemotherapy,":[56],"were":[57,145,172,194],"treated":[58,146,173,347],"at":[59,106,147,174,180,212,348],"successive":[60],"levels":[62],"(DLs)":[63],"cohorts":[65],"3-6":[67],"escalated":[69],"doses":[70],"70-100":[73],"mg/m(2)":[74],"over":[75,87,92],"1":[76,80,93,142],"h":[77],"day":[79],"followed":[81],"by":[82],"5-6":[84],"g/m(2)":[85],"divided":[86],"days":[88],"1+2":[89],"(2.5-3.0":[90],"g/m(2)/day":[91],"h),":[94],"every":[95],"21":[96,152],"days.":[97],"G-CSF":[98,207],"was":[99,104,183,210,250,297],"added":[100],"once":[101],"neutropenia":[103,272,282],"encountered":[105],"certain":[108],"DL":[109],"planned":[111],"be":[113],"incorporated":[114],"prophylactically":[115],"subsequent":[117],"higher":[118],"DLs.":[119],"Between":[120],"March":[121],"1997":[122],"December":[124],"2002,":[125],"65":[126],"patients":[127,179,193,217],"median":[130,247,255,262],"age":[131],"57":[133],"years":[134],"(range,":[135,143],"32-72)":[136],"performance":[138],"status":[139],"(WHO)":[140],"0-2)":[144],"5":[148],"DLs":[149,156],"follows;":[151],"I":[155],"(DL1:":[157],"3,":[158,162],"DL2:":[159],"6,":[160,164],"DL3:":[161],"DL4:":[163],"DL5:":[166],"3)":[167],"remaining":[170],"44":[171],"DL4":[175],"(total":[176],"50":[178],"DL4),":[181],"which":[182],"defined":[184,372],"level":[187],"for":[188,196,200],"II":[190,231,350,387],"testing.":[191],"All":[192],"assessable":[195],"toxicity":[197,313,330],"62":[199],"response.":[201],"DLT":[202],"(with":[203],"addition":[205],"DL2)":[209],"reached":[211],"DL5":[213],"2/3":[215],"initial":[216],"developing":[218,279],"febrile":[219,290],"neutropenia.":[220],"Clinical":[221],"response":[222,248],"rates":[223],"(RRs),":[224],"an":[226],"intention-to-treat":[227],"basis,":[228],"were:":[232],"56%;":[233],"(95%":[234],"CI,":[235],"42.2-69.7%);":[236],"4":[237,281],"CRs,":[238],"24":[239],"PRs,":[240],"10":[241],"SD":[242],"12":[244],"PD.":[245],"duration":[249],"7":[251],"mo":[252,258,265],"(3-24":[253],"mo),":[254,260],"TTP":[256],"6.5":[257],"(0.1-26":[259],"OS":[263],"13":[264],"(0.1-33":[266],"mo).":[267],"Grade":[268],"3/4":[269,295],"included:":[271],"72%":[274],"patients,":[276],"60%":[278],"grade":[280,294,304,309,319,324,334],"(